Expert Delphi panel reaches consensus on orthobiologics use

An international 24-member Delphi panel developed and voted on statements addressing best practices for orthobiologic therapies, including PRP, bone marrow aspirate concentrate, autologous conditioned serum, amniotic derivatives, gene therapy, and exosomes. Across three survey rounds, consensus rose from 48.1% to 96.8% of statements, with agreement reached on PRP use for knee, hip, and glenohumeral osteoarthritis, Achilles tendinopathy, lateral epicondylitis, rotator cuff tendinitis, and meniscus repair augmentation, though statements on PRP for rotator cuff repair augmentation and autologous cell-based therapies did not reach consensus. The authors state that many adopted statements retained qualifying language, reflecting continued uncertainty around dosing, preparation methods, and quality control that they say requires standardization for reproducible treatment effects.

Most relevant for: Clinicians managing musculoskeletal conditions such as knee, hip, or glenohumeral osteoarthritis, Achilles tendinopathy, lateral epicondylitis, rotator cuff tendinitis, or meniscus injury who are considering orthobiologic therapies.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.